Pacific Bio (PACB) Misses Q2 EPS by 2c

Pacific Bio (NASDAQ: PACB) reported Q2 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $24.9 million versus the consensus estimate of $26.36 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Morgan Stanley Downgrades Cosmos Pharmaceuticals Corp. (3349:JP) (CSMYF) to Equalweight
• Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP